ストックスクリーナーアプリを入手
0.9579
3.21%
0.0298
アフターアワーズ：
1.00
0.0421
+4.40%
前日終値:
$0.9281
開ける：
$0.9199
24時間の取引高:
78,382
Relative Volume:
0.41
時価総額：
$57.80M
収益：
-
当期純損益:
$-112.67M
株価収益率:
-0.454
EPS:
-2.11
ネットキャッシュフロー:
$-79.26M
1週間 パフォーマンス:
-2.25%
1か月 パフォーマンス:
+11.38%
6か月 パフォーマンス:
-7.89%
1年 パフォーマンス:
-14.47%
1日の値動き範囲:
$0.9199
$0.97
1週間の範囲:
$0.91
$1.03
52週間の値動き範囲:
$0.69
$1.60
Kronos Bio Inc Stock (KRON) Company Profile
KRON を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
KRON
Kronos Bio Inc
|
0.9579 | 57.80M | 0 | -112.67M | -79.26M | -1.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Kronos Bio Inc Stock (KRON) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-11-14 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2024-11-14 | ダウングレード | TD Cowen | Buy → Hold |
| 2022-09-14 | 開始されました | Berenberg | Buy |
| 2021-10-20 | 再開されました | Cowen | Outperform |
| 2021-06-24 | 開始されました | H.C. Wainwright | Buy |
| 2020-11-03 | 開始されました | Cowen | Outperform |
| 2020-11-03 | 開始されました | Goldman | Buy |
| 2020-11-03 | 開始されました | Jefferies | Buy |
| 2020-11-03 | 開始されました | Piper Sandler | Overweight |
すべてを表示
Kronos Bio Inc (KRON) 最新ニュース
Layoff Tracker: Editas Will Cut 60% of Staff - BioSpace
Kronos Bio (NASDAQ:KRON) Trading 8.5% HigherHere's Why - MarketBeat
Struggling Bay Area biotech firm Kronos, once worth $1B, lays off almost entire staff - SFGATE
Kronos Bio, Inc. (KRON) Reports Q3 Loss, Tops Revenue Estimates - MSN
KRON (Kronos Bio) Profitability Rank : 1 (As of Sep. 2024) - GuruFocus.com
A Look At The Behavior Of Kronos Bio Inc (KRON) Stock - Stocks Register
Kronos Bio announces interim CEO; over 80% of staff reduction - MSN
Kronos Bio announces interim CEO and workforce cuts of 83% - Yahoo Finance
Kronos Bio Stock Jumps After Deep Workforce Cuts And CEO Shuffle: Retail Aligns With Shake-Up - MSN
Strategic shift at Kronos creates CEO vacancy - The Pharma Letter
Kronos Bio to lay off 83% of staff as CEO steps down - The Business Journals
Kronos Bio announces layoffs and executive changes By Investing.com - Investing.com Nigeria
Kronos Bio, Inc. Announces Management Changes, Effective December 3, 2024 - Marketscreener.com
Kronos Bio, Inc. Announces CEO Changes, Effective December 3, 2024 - Marketscreener.com
Kronos Bio Shakes Up LeadershipCuts 83% Of Workforce Amid Strategic Overhaul - AOL
Biotech with Cambridge lab slashes 83% of staff, CEO departs - NBC Boston
Kronos Bio announces layoffs and executive changes - Investing.com India
Kronos Bio Announces CEO Transition and Reduction in Force - The Manila Times
Kronos Bio stock in focus on CEO change, layoffs (KRON:NASDAQ) - Seeking Alpha
Kronos Bio to Cut 83% Of Workforce, Names Interim CEO - MarketWatch
Kronos Bio Cuts 83% of Workforce, Names New CEO Amid Strategic Review | KRON Stock News - StockTitan
Kronos Bio Restructures Workforce and Leadership - TipRanks
Kronos Bio : Management Change/Compensation Form 8 K - Marketscreener.com
Kronos, Idorsia plan layoffs; PTC shelves ALS drug - Yahoo Finance
KRON (Kronos Bio) Cash Flow from Discontinued Operations : $0.00 Mil (TTM As of Sep. 2024) - GuruFocus.com
Petri Dish: Kronos Bio seeks merger; Former Biogen R&D head joins investment firm - The Business Journals
Kronos Bio downgraded by Piper Sandler, TD Cowen - MSN
Kronos Bio Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Kronos Bio Provides Update on Review of Strategic Alternatives - Marketscreener.com
Kronos Bio shares downgraded to hold by TD Cowen - Investing.com Australia
Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024 - The Manila Times
Kronos Bio Highlights Preclinical Data that Show p300 KAT - GlobeNewswire
Kronos Bio's KB-7898 Shows 50% Reduction in Inflammation Markers in Preclinical Study | KRON Stock News - StockTitan
Kronos Bio stock takes a hit with piper sandler slashing price target - Investing.com
Kronos mulls ‘strategic alternatives’ after axing cancer drug development - Pharmaceutical Technology
Kronos Bio (NASDAQ:KRON) Rating Lowered to "Hold" at TD Cowen - MarketBeat
Kronos Bio downgraded by Piper Sandler, TD Cowen (NASDAQ:KRON) - Seeking Alpha
Kronos Bio earnings beat by $0.05, revenue topped estimates - Investing.com UK
Kronos Bio Reports Third Quarter 2024 Financial Results and Corporate Update Including Plan to Evaluate Strategic Alternatives - The Manila Times
Kronos Bio Reports Third Quarter 2024 Financial Results and - GlobeNewswire
Kronos Bio Halts Cancer Drug Trial, Explores Strategic Alternatives Amid Safety Concerns | KRON Stock News - StockTitan
Kronos Bio's Market Cap Drops To US$50m Leaving Insiders With Losses - Simply Wall St
Kronos Bio faces Nasdaq delisting over share price - Investing.com India
Kronos Bio faces Nasdaq delisting over share price By Investing.com - Investing.com UK
Kronos Bio Inc (KRON) 財務データ
収益
当期純利益
現金流量
EPS
2.88%
2.65%
大文字化:
|
ボリューム (24 時間):